Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.72 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.72 |
| ▸ | LCK | P06239 | 2/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL759064 | 0.94 | AURKA (0.69) | AURKATNK2LCKKDM4EUSP2 | |
| SCHEMBL764292 | 0.93 | LCK (0.80) | AURKATNK2LCKAURKBEGFR | |
| SCHEMBL757476 | 0.93 | AURKA (0.74) | AURKATNK2LCKAURKBEGFR | |
| SCHEMBL759053 | 0.93 | AURKA (0.78) | AURKATNK2LCKKDM4EUSP2 | |
| SCHEMBL757483 | 0.92 | AURKA (0.68) | AURKATNK2LCKKDM4EUSP2 | |
| SCHEMBL757342 | 0.90 | AURKA (0.73) | AURKATNK2LCKKDM4EUSP2 | |
| SCHEMBL757779 | 0.90 | AURKA (0.78) | AURKATNK2LCKKDM4EUSP2 | |
| SCHEMBL757479 | 0.87 | LCK (0.70) | AURKATNK2LCKAURKBEGFR | |
| SCHEMBL759002 | 0.87 | AURKA (0.79) | AURKATNK2LCKKDM4EUSP2 | |
| SCHEMBL759066 | 0.87 | AURKA (0.69) | AURKATNK2LCKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276346-B1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2016-11-23 | — | — | EP | disclosed |
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| US-8138194-B2 | Fused bicyclic pyrimidine compounds as aurora kinase inhibitors | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2012-03-20 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | US | disclosed |
| WO-2009134658-A2 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275533-A1 | FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS | AURKB, AURKA, AURKC | AURKA 2/4885TNK2 193/4885LCK 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.